Dynavax Technologies (NASDAQ:DVAX) Stock Price Up 15.6%

Shares of Dynavax Technologies Co. (NASDAQ:DVAX) shot up 15.6% during mid-day trading on Monday . The stock traded as high as $6.69 and last traded at $6.59, 3,144,929 shares were traded during mid-day trading. An increase of 140% from the average session volume of 1,312,619 shares. The stock had previously closed at $5.70.

Several research firms have commented on DVAX. HC Wainwright reiterated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, December 4th. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a research note on Friday, December 6th. Finally, BidaskClub raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.63.

The firm has a market cap of $582.86 million, a PE ratio of -2.62 and a beta of 0.56. The stock’s fifty day moving average price is $5.49 and its 200-day moving average price is $4.37. The company has a debt-to-equity ratio of 5.48, a current ratio of 4.94 and a quick ratio of 4.09.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.10). The business had revenue of $10.58 million during the quarter, compared to analysts’ expectations of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The business’s quarterly revenue was up 624.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.65) earnings per share. On average, sell-side analysts anticipate that Dynavax Technologies Co. will post -2.04 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in DVAX. BlackRock Inc. raised its holdings in Dynavax Technologies by 7.9% in the 2nd quarter. BlackRock Inc. now owns 4,570,570 shares of the biopharmaceutical company’s stock valued at $18,236,000 after acquiring an additional 332,875 shares during the last quarter. Chicago Capital LLC grew its position in shares of Dynavax Technologies by 49.1% in the third quarter. Chicago Capital LLC now owns 4,380,216 shares of the biopharmaceutical company’s stock valued at $15,659,000 after purchasing an additional 1,442,950 shares in the last quarter. Senvest Management LLC grew its position in shares of Dynavax Technologies by 20.1% in the second quarter. Senvest Management LLC now owns 3,949,052 shares of the biopharmaceutical company’s stock valued at $15,757,000 after purchasing an additional 660,526 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Dynavax Technologies by 15.2% in the second quarter. Vanguard Group Inc. now owns 3,603,383 shares of the biopharmaceutical company’s stock valued at $14,377,000 after purchasing an additional 475,003 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its holdings in shares of Dynavax Technologies by 103.2% in the second quarter. UBS Asset Management Americas Inc. now owns 1,741,907 shares of the biopharmaceutical company’s stock valued at $6,950,000 after purchasing an additional 884,854 shares during the last quarter. 82.40% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile (NASDAQ:DVAX)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

See Also: Bond

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.